Effects of Healing Touch on Patients Undergoing Hematopoietic Stem Cell Transplant

N/ACompletedNCT02194413

University of Iowa60 enrolled

Overview

This randomized pilot clinical trial studies healing touch or usual care in improving quality of life in patients undergoing stem cell transplant. Healing touch may improve the quality of life of patients undergoing stem cell transplant.

Primary Objectives: I. To estimate the effects of healing touch (HT) vs usual care in the following clinical outcomes of stem cell transplant (SCT) patients; length of hospital stay, days to engraftment, and number of hospital readmissions during 100 days post-transplant. II. To estimate changes in quality of life (QoL) which occur during hospitalization of SCT patients who receive HT vs. usual care. III. To examine differences in effects of HT vs. usual care (UC) in patients receiving related allogeneic (Allo) transplant compared to those receiving autologous (Auto) transplant. OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients receive daily HT sessions comprising pain drain, chakra connection, magnetic clearing, and mind clearing over 30 minutes from day 1 until 2 days before discharge from the hospital. ARM II: Patients receive routine nursing care from doctors and nurses from day 1 until 2 days before discharge from the hospital. After completion of study treatment, patients are followed up for 100 days.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

SUPPORTIVE_CARE

Masking

NONE

Enrollment

Conditions

Anxiety Disorder Fatigue Hematopoietic/Lymphoid Cancer Pain

Interventions

therapeutic touchPROCEDURE

receiving healing touch

quality-of-life assessmentOTHER

Ancillary studies

questionnaire administrationOTHER

Ancillary studies

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Currently undergoing autologous (auto) or related allogeneic (related allo) stem cell transplantation * Admitted to the University (U) Adult Blood and Bone Marrow Transplant Unit (UIBMTU) of the University of Iowa Hospitals and Clinic * Ability to provide written informed consent obtained prior to participation in the study and able to complete questionnaires * Pregnant woman who are eligible for stem cell transplant are included in this study Exclusion Criteria: * Patients with any significant history of non-compliance to medical regimens, with inability to grant a reliable informed consent or unable to complete questionnaires * Patients with evidence of a significant psychiatric disorder by history that would prevent completion of the study will not be allowed to participate, i.e., schizophrenia, anxiety disorder, major depressive disorder and bipolar disorder * Diagnosis of dementia or other disease affecting cognitive function * Nursing women are excluded

Locations (1)

University of Iowa Hospitals and Clinics

Iowa City, Iowa, United States

Outcomes

Primary Outcomes

Length of hospital stay, Days to engraftment defined as absolute neutrophil count (ANC: segs + bands) greater

Time frame: Up to 100 days

Changes in QoL (POMS-SF, FACT-BMT, CES-D)

Changes in levels of QoL measures before and after hospitalization will be compared using the paired t-test or the nonparametric paired sign test, if the assumption of normality is substantially violated.

Time frame: Baseline up to 100 days

Secondary Outcomes

Number of hospital readmissions

Time frame: Up to 100 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.